Brokers Issue Forecasts for Sanofi’s Q1 2024 Earnings (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) – Analysts at Leerink Partnrs lowered their Q1 2024 earnings per share (EPS) estimates for Sanofi in a note issued to investors on Tuesday, April 16th. Leerink Partnrs analyst D. Risinger now expects that the company will earn $0.94 per share for the quarter, down from their previous estimate of $0.98. The consensus estimate for Sanofi’s current full-year earnings is $4.16 per share. Leerink Partnrs also issued estimates for Sanofi’s FY2024 earnings at $3.97 EPS, FY2025 earnings at $4.44 EPS and FY2028 earnings at $5.34 EPS.

Several other research analysts have also recently commented on the company. Morgan Stanley started coverage on Sanofi in a research report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 target price for the company. TheStreet cut Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. Finally, StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $55.00.

Sanofi Stock Up 0.7 %

Shares of SNY stock opened at $46.11 on Thursday. The stock has a market cap of $116.64 billion, a P/E ratio of 19.54, a price-to-earnings-growth ratio of 1.71 and a beta of 0.61. Sanofi has a one year low of $42.63 and a one year high of $57.82. The stock has a fifty day moving average price of $47.55 and a 200 day moving average price of $48.69. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.94 by ($0.05). The business had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $13.02 billion. Sanofi had a net margin of 12.56% and a return on equity of 27.47%.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. SRS Capital Advisors Inc. increased its stake in shares of Sanofi by 289.1% in the first quarter. SRS Capital Advisors Inc. now owns 463 shares of the company’s stock valued at $25,000 after buying an additional 344 shares in the last quarter. Rise Advisors LLC increased its stake in shares of Sanofi by 98.4% in the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after buying an additional 251 shares in the last quarter. Fairfield Bush & CO. acquired a new stake in shares of Sanofi in the first quarter valued at $26,000. Householder Group Estate & Retirement Specialist LLC acquired a new stake in shares of Sanofi in the third quarter valued at $26,000. Finally, Salem Investment Counselors Inc. acquired a new stake in shares of Sanofi in the fourth quarter valued at $27,000. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be paid a dividend of $1.478 per share. This is a positive change from Sanofi’s previous annual dividend of $1.38. This represents a yield of 2.98%. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi’s dividend payout ratio is currently 58.47%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.